Black Diamond Therapeutics filings document financial results, clinical-program disclosures and governance matters for a Nasdaq-listed clinical-stage oncology company. Recent Form 8-K reports furnish quarterly and annual operating results and corporate updates tied to silevertinib, the company’s EGFR MasterKey inhibitor program for EGFR-mutant NSCLC and glioblastoma, along with liquidity and capital-expenditure commentary.
Proxy materials disclose annual meeting matters, including board-class elections, auditor ratification, advisory executive-compensation votes and the preferred frequency of future compensation votes. The filings also identify the company’s registered common stock, par value and Nasdaq Global Select Market listing under the BDTX symbol.
Black Diamond Therapeutics, Inc. reported a net loss of $9.0 million for the quarter ended March 31, 2026, compared with net income of $56.5 million a year earlier, when it recorded a $70.0 million upfront license payment from Servier.
Research and development expense declined to $7.0 million from $10.5 million, reflecting lower NSCLC spending and the out‑licensing of BDTX‑4933, partially offset by higher GBM costs. General and administrative expense fell to $4.3 million from $5.0 million due to operational efficiencies.
The company ended the quarter with $118.3 million in cash, cash equivalents and investments and expects this to fund operations into the second half of 2028. Lead EGFR inhibitor silevertinib is in Phase 2 trials for NSCLC and newly diagnosed EGFR‑altered glioblastoma.
Black Diamond Therapeutics, Inc. reported first quarter 2026 results, showing a net loss of $9.0 million after earning $56.5 million in the same period of 2025, mainly because prior-year license revenue of $70.0 million did not recur. Cash, cash equivalents and investments were $118.3 million as of March 31, 2026, and the company believes this will fund operations into the second half of 2028. R&D and G&A expenses declined year over year as the company sharpened its focus on silevertinib. Clinically, Black Diamond dosed the first patient in its randomized Phase 2 trial of silevertinib in newly diagnosed EGFRvIII+ GBM and plans multiple silevertinib data presentations at the 2026 ASCO Annual Meeting.
Black Diamond Therapeutics, Inc. is asking stockholders to vote at its 2026 virtual annual meeting on June 26, 2026. The agenda includes electing two Class III directors to serve until 2029, ratifying PricewaterhouseCoopers LLP as auditor for 2026, and two advisory votes on executive pay and how often future “Say‑on‑Pay” votes should occur.
Only holders of the company’s common stock at the close of business on April 28, 2026, when 57,301,774 shares were outstanding, may vote. Stockholders can vote online, by telephone, by mail, or during the live webcast. The board recommends voting in favor of all proposals and for an annual Say‑on‑Pay frequency.
Behbahani Ali reported acquisition or exercise transactions in this Form 4 filing.
Black Diamond Therapeutics director Ali Behbahani received a grant of 6,919 shares of common stock on March 20, 2026. The award was made under the company’s non-employee director compensation policy, as he elected to take stock instead of cash fees for his annual board service.
The grant was valued at $2.15 per share, based on the closing market price on March 19, 2026. After this award, Behbahani directly holds 93,568 common shares. The filing also reports 4,448,757 shares held indirectly through New Enterprise Associates 16, L.P., where he disclaims beneficial ownership for portions in which he has no pecuniary interest.
Raman Prakash reported acquisition or exercise transactions in this Form 4 filing.
Black Diamond Therapeutics director Raman Prakash received 6,105 shares of Common Stock as compensation. The shares were issued under the company’s non-employee director compensation policy, where he elected stock instead of cash for annual board service. The grant was valued at $2.15 per share, bringing his direct holdings to 37,132 shares.
Black Diamond Therapeutics is a clinical-stage oncology company focused on “MasterKey” small-molecule therapies that target families of oncogenic mutations in genetically defined cancers. Its lead candidate, silevertinib, a brain‑penetrant, fourth‑generation EGFR inhibitor, is in Phase 2 trials for non‑small cell lung cancer (NSCLC) and being advanced toward a randomized Phase 2 trial in newly diagnosed EGFR‑altered glioblastoma (GBM).
Initial Phase 2 frontline NSCLC data in 43 patients with non‑classical EGFR mutations showed a 60% objective response rate and 86% CNS response rate at a 200 mg daily dose, with manageable rash, stomatitis, diarrhea and paronychia. The company plans updated NSCLC data and FDA discussions on a potential pivotal design in 2026, and an interim GBM progression‑free survival analysis is anticipated in the first half of 2028.
Black Diamond also outlicensed RAF inhibitor BDTX‑4933 to Servier, receiving a $70.0 million upfront payment and eligibility for up to $710.0 million in milestones plus tiered royalties, and is seeking partners for FGFR2/3 candidate BDTX‑4876. As of June 30, 2025, non‑affiliate market value was approximately $113.8 million, and as of March 11, 2026, there were 57,288,750 common shares outstanding.
Black Diamond Therapeutics reported a major financial turnaround for 2025, driven by $70.0 million in license revenue and sharply lower operating expenses. The company posted full-year net income of $22.4 million, compared to a net loss of $69.7 million in 2024, while ending 2025 with $128.7 million in cash, cash equivalents, and investments.
Research and development expenses fell to $33.6 million and general and administrative expenses to $16.6 million for the year, reflecting workforce and operational efficiencies. Management expects its cash balance to fund operations into the second half of 2028, supporting ongoing Phase 2 development of silevertinib in EGFR-mutant NSCLC and EGFR‑altered GBM, including a planned randomized GBM trial starting in the second quarter of 2026.
Vestal Point Capital and Ryan Wilder filed an amended Schedule 13G reporting passive ownership in Black Diamond Therapeutics, Inc. common stock. They report beneficial ownership of 870,000 shares, representing 1.5% of the company’s common stock outstanding as of October 30, 2025.
The shares are held through a fund and managed account advised by Vestal Point Capital, with shared voting and dispositive power over all 870,000 shares. The filers state the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Black Diamond Therapeutics.
Black Diamond Therapeutics, Inc. reports an option grant to senior management. Officer Erika Jones, who serves as Senior Vice President, Finance and Corporate Controller, was granted a stock option to purchase 200,000 shares of common stock at an exercise price of $2.57 per share on January 21, 2026.
According to the vesting terms, 25% of the shares subject to this option will vest and become exercisable on January 21, 2027. The remaining 75% will vest in 36 equal monthly installments after that date, contingent on her continued service with the company. Following this grant, she holds 200,000 derivative securities (stock options) directly.